Advertisement
Advertisement
MNKD
Mannkind Corporation
4.23
USDSponsored
+0.04
+0.95%
Nov 10, 15:59 UTC -5
Closed
After-Market
4.14
-0.09
-2.01%
Mannkind Corporation (MNKD) Earnings
MNKD Earnings Reports
Positive Surprise Ratio
MNKD beat 18 of 44 last estimates.
41%
Next Report
Date of Next Report
Feb 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
$134.44M
/$0.00
Implied change from Q3 26 (Revenue/ EPS)
+31.97%
/-100.00%
Implied change from Q4 25 (Revenue/ EPS)
+20.08%
/-100.00%
Mannkind Corporation earnings per share and revenue
On Nov 05, 2026, MNKD reported earnings of -0.07 USD per share (EPS) for Q3 26, missing the estimate of -0.05 USD, resulting in a -19.25% surprise. Revenue reached 101.87 million, compared to an expected 109.91 million, with a -7.31% difference. The market reacted with a +3.72% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 6 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 134.44 million USD, implying an decrease of -100.00% EPS, and increase of 31.97% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Mannkind Corporation's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Mannkind Corporation reported EPS of -$0.07, missing estimates by -19.25%, and revenue of $101.87M, -7.31% below expectations.
How did the market react to Mannkind Corporation's Q3 2026 earnings?
The stock price moved up 3.72%, changed from $3.76 before the earnings release to $3.90 the day after.
When is Mannkind Corporation expected to report next?
The next earning report is scheduled for Feb 24, 2027.
What are the forecasts for Mannkind Corporation's next earnings report?
Based on 6
analysts, Mannkind Corporation is expected to report EPS of -- and revenue of $134.44M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.